VA Officials To Testify At Congressional Hearing On Psychedelic Therapy For Veterans

VA Officials To Testify At Congressional Hearing On Psychedelic Therapy For Veterans

VA Officials Set To Testify On Psychedelic Therapy For Veterans

A congressional hearing on expanding military veterans’ access to psychedelic treatments is scheduled for Wednesday before the House Veterans’ Affairs Subcommittee on Health. The hearing is titled “Psychedelic-Assisted Therapies for Veterans: The Path Forward.” Officials from the U.S. Department of Veterans Affairs will testify alongside medical professionals and researchers.

Andrew Gradison, a senior advisor to the under secretary for health at the VA’s Veterans Health Administration, said in written testimony posted by the panel that the Trump administration “has taken decisive action to accelerate psychedelic research and eliminate regulatory obstacles that have historically slowed progress.” He cited an executive order Trump signed in April aimed at expediting psychedelic therapy access. He described it as the “first EO in American history dedicated specifically to accelerating clinical research and regulatory review of psychedelics,” according to his written testimony.

Gradison said the VA is now conducting 21 active clinical studies on psychedelics to treat mental health conditions. He noted a clinical trial the VA announced in August to investigate whether psilocybin can help veterans with treatment-resistant depression. He said the department recognizes that substances such as psilocybin, MDMA and ibogaine “offer promising potential for the complex mental health conditions affecting many of the Veterans we treat.”

Gradison also highlighted a memorandum of understanding the VA signed with the Department of Health and Human Services in July to collaborate on psychedelic medicine research. The agreement, he said, “lays the groundwork for unprecedented VA-HHS operational cooperation on psychedelic trials.”

The VA has identified 10 facilities with the expertise, space and operational capacity to serve as early implementers, educators, or sites-in-training. Gradison emphasized that the department discourages veterans from self-medicating with psychedelics or using them to replace other mental health treatment.

Witnesses Call For Research And Readiness

Leith States, a former HHS acting assistant secretary for health who now runs the consulting firm States Strategies, is also testifying. He is calling on Congress to support psychedelic research that “answers the clinical questions veterans and clinicians face.”

States urged requiring the VA to set and track milestones for clinical readiness and access. His testimony said Congress should hold the department accountable for patient safety and lasting improvement in veterans’ lives.

“Doing our duty means investigating promising treatments with urgency and discipline, speaking plainly about what we know, and preparing the people and systems needed to deliver responsible, safe, and ethical care,” States’s testimony said.

He added that veterans’ needs should determine priorities as the work builds on efforts across administrations. His testimony called for examining shortcomings honestly and sustaining progress for clinicians and researchers.

Infrastructure Questions Take Center Stage

Marion Coe of Pinney Associates will also testify at Wednesday’s hearing. Her testimony references her work compiling responses to a request for information issued by the bipartisan Congressional Psychedelics Advancing Therapies (PATH) Caucus.

The caucus sought input from experts about how to best set up a regulatory framework for psychedelic medicines. Coe emphasized that the VA must “begin preparing its clinical infrastructure and workforce” before FDA approval of any psychedelic treatments.

Related Stories

Friday
administrator
Friday is a San Diego based writer covering cannabis news, culture, and business. Known for sharp analysis and clean reporting, Friday helps readers navigate the industry without the fluff. Every article is built on research, real sources, and a deep commitment to the cannabis community.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *